Refine by
Drug Monitoring Articles & Analysis: Older
17 news found
For Biomedical research, R-PE labeled proteins can be used as fluorescent probes for drug efficacy, biological molecular components, biomarker and diagnostic and therapeutic methods. In Clinical trials, R-PE labeled proteins can be used for dynamic monitoring of drugs and pharmacokinetic studies. With a complete, professional, as well as an ...
BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. ...
Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid samples, monitoring of drug responses and organ-specific metabolic phenotyping, and precision nutrition to therapeutic ...
The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. Dose modifications can be made based on Aurinia’s proprietary personalized eGFR-based dosing protocol. ...
The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. Dose modifications can be made based on Aurinia’s proprietary personalized eGFR-based dosing protocol. ...
The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. Dose modifications can be made based on Aurinia’s proprietary personalized eGFR-based dosing protocol. ...
(Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that ...
The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. Dose modifications can be made based on Aurinia’s proprietary personalized eGFR-based dosing protocol. ...
These new assays are developed using an innovative nanoparticle technology and empower health care professionals with data to monitor psychiatric drugs prescribed in treatment of psychosis: Clozapine, Risperidone/Paliperidone, Olanzapine, Quetiapine, Aripiprazole. ...
Compared to the active control group, the voclosporin-treated group showed an increase from baseline eGFR at the end of the studies of +2.7 mL/min. The drug was well tolerated with no unexpected safety signals observed. There were comparable serious adverse events (SAEs) rates in both arms (19% voclosporin vs. 24% control). ...
The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. Dose modifications can be made based on Aurinia’s proprietary personalized eGFR-based dosing protocol. ...
The Notal Home OCT pipeline technology is designed to provide patient-initiated retinal OCT scans to support the management of patients with wet age-related macular degeneration (AMD), complementing existing standard of care treatments as well as emerging longer acting drugs and drug delivery systems. The study evaluated the ability of subjects with wet AMD to ...
Pippenger Award at the 2021 International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting in Rome, Italy. This award is given to individuals who have made outstanding contributions to the field of Therapeutic Drug Monitoring (TDM). TDM is a field of medical science that seeks to ensure ...
MOBILion Systems Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and biotherapeutic drug characterization, today announced the close of a $60 million Series C financing round. ...
MOBILion Systems Inc. has today announced the launch of its first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE, which addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE provides fast, efficient separations with superior resolution and reproducibility, faster, simpler method ...
The Inhalation Translation challenge aims to identify solutions that have the potential to reduce the numbers of animals used at certain stages of drug discovery and development by up to 90%. The National Centre of Excellence in Mass Spectrometry Imaging (NiCE-MSI), which is based at NPL and was established in partnership with the University of Nottingham, is contributing ...
Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. ...